The first evaluable patient in Cohort 2 (Patient 6) demonstrated a clear dose response, and early MyBP-C expression increased by 14% after only 12 weeks post-dose. Of note, Patient 6 had a greater ...

The company reported $200 million in net losses for the third quarter, but an aggressive and highly successful cost-cutting ...

Hosts David and Gina explore the unexpected origins of blockbuster diabetes and weight-loss drugs like Ozempic and Wegovy ...

Researchers can use messenger RNA to trigger the immune system to attack tumors. By stimulating cancer cells to produce a ...

The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems to help fight tumors. Research reported recently in the journal Nature ...

Tumors were eradicated in 30% of mice receiving cGAS LNPs injected into the tumor, in combination with immune checkpoint blockade.

Q3 2025 Earnings Call Transcript November 3, 2025 BioNTech SE misses on earnings expectations. Reported EPS is $-0.14 EPS, ...

An update from Veritas In Silico Inc. ( ($JP:130A) ) is now available. Veritas In Silico Inc. and Dexerials Corporation have announced a joint ...

By stimulating cancer cells to produce a molecule that activates a signaling pathway in nearby immune cells, MIT researchers ...

By stimulating cancer cells to produce a molecule that activates a signaling pathway in nearby immune cells, MIT researchers ...

Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting ...